Estimation of StilbostatR treatment efficiency in breast cancer by thermography

Administration of Stilbostat to postmenopasual women with advanced breast cancer markedly improved the clinical state in about 65% of the cases and concomitantly decreased the cutaneous thermic values at the level of the lesions showing a tendency to equalize the values recorded for the symmetrical healthy cutaneous zones. The thermographic test is proposed as a means of estimating the Stilbostat treatment efficiency in breast cancer.